Melanotan I: what the MC1R agonist is and what the research actually shows

What Melanotan I is

Melanotan I, also known as afamelanotide, is a synthetic analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH is a 13-amino-acid peptide that binds to melanocortin receptors, with MC1R being the primary receptor responsible for melanin production in melanocytes.

Structurally, Melanotan I is a cyclic analogue. It contains a ring structure formed by an amide bond between aspartate and lysine residues, which makes it significantly more resistant to enzymatic degradation than native alpha-MSH. This structural feature also gives it a higher binding affinity for MC1R than the endogenous hormone itself. Compared to Melanotan II, Melanotan I is notably more receptor-selective: it binds primarily at MC1R without the broader melanocortin receptor activity seen with Melanotan II.

Afamelanotide has been developed into a licensed pharmaceutical product in the UK and EU under the brand name Scenesse, approved for erythropoietic protoporphyria (EPP) by the European Medicines Agency. That pharmaceutical product and the research reference material share the same amino acid sequence but are categorically different products: one is a GMP-manufactured licensed medicine supplied through authorised clinical channels; the other is a research compound for laboratory use.

MC1R is the primary receptor linking melanocortin signalling to melanin production. When MC1R is activated in melanocytes, the intracellular cAMP cascade drives upregulation of tyrosinase and related enzymes, ultimately increasing melanin synthesis. The specificity of Melanotan I for MC1R, compared to the broader receptor activity of other melanocortin peptides, makes it a particularly useful tool for MC1R-focused research questions.

In biochemical terms, the cyclic structure of Melanotan I is the key feature distinguishing it from both native alpha-MSH and from Melanotan II. The ring prevents the conformational flexibility that makes linear peptides susceptible to rapid proteolytic cleavage. This extended stability is part of what made afamelanotide suitable for pharmaceutical development: a longer-acting analogue that could be administered less frequently than a native peptide would require.

What the research literature has examined

Melanotan I has a comparatively well-developed research history because afamelanotide has been studied clinically as a pharmaceutical candidate:

Erythropoietic protoporphyria

Afamelanotide is the most clinically studied melanocortin analogue. EPP is a rare metabolic disorder caused by a deficiency of ferrochelatase, the enzyme that catalyses the final step of haem synthesis. The result is accumulation of protoporphyrin IX, which causes severe phototoxic reactions on sun exposure. The clinical research into afamelanotide for EPP was conducted using the GMP pharmaceutical product, not a laboratory research compound. Those trial data relate to a specific pharmaceutical dosing protocol in a clinical population under a licensed medicine framework.

Photodermatosis research

Beyond EPP, afamelanotide has been investigated in various photodermatoses and light-related skin conditions. The research interest stems from the role of MC1R activation in increasing skin melanin content, which in principle provides some degree of UV protection. Again, published clinical research in this area relates to the pharmaceutical product under controlled conditions, not to research reference materials.

MC1R pharmacology

As a selective MC1R agonist, Melanotan I is a valuable research tool for fundamental pharmacology of the melanocortin-1 receptor. MC1R has roles beyond simple pigmentation: it is involved in anti-inflammatory signalling, UV-response pathways, and has been studied in the context of skin cancer risk modulation. The selectivity of Melanotan I for MC1R, compared to Melanotan II which also activates MC3R, MC4R and MC5R, makes it the preferred tool for studies specifically examining MC1R-mediated pathways without confounding signals from other receptor subtypes.

Melanogenesis research

Melanin production in melanocytes is an active research field. MC1R agonists including Melanotan I are used as tools in cell biology studies examining melanogenesis, the signalling cascades downstream of MC1R, and the regulation of tyrosinase activity. In vitro experiments in melanocyte cell lines and related cell models are the typical context for this kind of research.

Laboratory context

Research compounds used in laboratory settings serve a fundamentally different purpose from pharmaceutical products used in clinical settings. In a laboratory, Melanotan I would typically be applied to cell cultures or other model systems at defined concentrations to study receptor binding, downstream signalling, or related biochemical questions. Results from such experiments are not directly transferable to predictions about human physiology. Researchers interpret laboratory data within the methodological constraints of the model system used.

For laboratory use, the chemical identity and consistency of the reference material are important. Batch documentation, where available from the supplier, is described on our documentation policy page. Where batch documentation exists, it is associated with the specific batch, not with the product line as a whole.

Melanotan I versus Melanotan II: the receptor selectivity difference

The two compounds are often discussed together but represent meaningfully different research tools. Melanotan I (afamelanotide) binds selectively to MC1R. Melanotan II is a cyclic heptapeptide with a D-phenylalanine substitution and C-terminal amide group, and it activates a broader range of melanocortin receptors: MC1R, MC3R, MC4R and MC5R.

This broader receptor activity has significant implications for research. MC4R activation is associated with effects on energy balance, appetite regulation, and sexual function in animal models. MC3R has roles in energy homeostasis. MC5R is expressed in exocrine glands. Melanotan II activating all four receptors simultaneously means its effects in research models are the result of multiple receptor pathways, which complicates interpretation.

For researchers specifically interested in MC1R-mediated signalling, Melanotan I is the more appropriate tool because it isolates the MC1R pathway without introducing off-target signals from other melanocortin receptors. For researchers interested in broader melanocortin system effects, particularly those involving MC4R, Melanotan II may be the relevant comparator.

In regulatory terms, the two compounds also sit differently. Melanotan I has a licensed pharmaceutical application as Scenesse for EPP. Melanotan II has no licensed pharmaceutical application in the UK or EU, and the EU Scientific Committee on Consumer Safety has determined it is not safe for cosmetic use. The regulatory contexts are distinct and both are described on our legal status page.

UK regulatory status

Afamelanotide (Scenesse) has received approval in the UK for the treatment of erythropoietic protoporphyria. As a licensed pharmaceutical product, it is a prescription-only medicine supplied through authorised clinical channels. That approval relates to the GMP pharmaceutical product, not to research reference materials sharing the same molecular structure.

Melanotan I is not approved for cosmetic use in the UK. Using it as a tanning injection or for any cosmetic purpose would be outside licensed use and could constitute unlicensed medicine supply under UK medicines law. The MHRA takes enforcement action in this area.

A research reference compound containing the same molecule, synthesised for in vitro laboratory research, is regulated differently. It is not a licensed medicine, is not subject to prescribing requirements in the same way, and cannot be marketed for human use. The line between research compound supply and unlicensed medicine supply is one Titeris does not blur. Every listing here is for research use only, and nothing on this site is an instruction or invitation to administer Melanotan I to a human or animal.

For a fuller explanation of how research compound supply relates to UK medicines law, see our legal status page.

Storage and handling notes for laboratory use

Lyophilised peptide reference materials are generally stored dry, away from light, and at low temperature to maintain chemical integrity over time. Freeze-drying removes water from the sample and creates a dry, stable matrix that remains usable for research purposes considerably longer than a reconstituted solution.

For Melanotan I as a lyophilised research material, storage at -20°C in dry conditions is the standard recommendation. The vial should be allowed to reach room temperature in closed condition before opening, to prevent moisture condensation inside. Once a vial has been opened, the protective inert atmosphere is no longer present, so prompt use or careful resealing is appropriate.

Reconstitution for laboratory use typically involves bacteriostatic water or sterile water, depending on the specific research application. Reconstituted solutions should be kept at 4°C and used promptly. Repeated freeze-thaw cycles of reconstituted solutions degrade the peptide through mechanical stress on the structure and should be avoided where possible. Aliquoting into single-use portions before freezing is the standard approach when extended storage of reconstituted material is needed.

Disposal of Melanotan I residues should follow institutional guidelines for chemical waste, in line with applicable UK environmental regulations. Researchers working with this material should follow their institution's standard operating procedures for compounds with potential biological activity.

Melanotan I in our catalogue

For laboratory use only. Not for human or veterinary consumption. See our documentation policy and UK legal status page.

Related compounds in our catalogue

Research protocols comparing related compounds often require multiple reference materials. Titeris stocks a range of research compounds including Melanotan II for comparative melanocortin receptor studies. When Melanotan I and Melanotan II are used together as research tools, the receptor selectivity difference between them allows researchers to isolate MC1R-specific effects from the broader melanocortin receptor responses. Our full catalogue is available on the shop page.

Good laboratory practice for mechanistic studies generally involves comparison across related compounds, appropriate controls including vehicle controls, and careful attention to concentration ranges. For multi-compound orders, contacting us directly is the most efficient route. We handle all orders through our contact page.

Frequently asked